Assessment of Potential Drug–Drug Interactions and Associated Factors Among Pulmonary Inpatients in a Tertiary Care Hospital: A Cross-Sectional Study - Report - MDSpire
Clinical Report: Evaluation of Possible Drug–Drug Interactions in Pulmonary Inpatients
Overview
This study found that 37.4% of pulmonary inpatients were exposed to at least one potential drug-drug interaction (pDDI).
Background
Pulmonary diseases are a major global health concern, with conditions like COPD contributing significantly to morbidity and mortality. Hospitalized patients often require complex medication regimens, increasing the risk of drug-drug interactions.
Data Highlights
In this study, 37.4% of pulmonary inpatients experienced at least one pDDI. Key predictors included:
Polypharmacy
Prolonged hospital stay
Co-morbidities
Alcohol use
Advanced age
Key Findings
37.4% of pulmonary inpatients were exposed to at least one pDDI.
Polypharmacy was identified as a significant predictor of pDDIs.
Prolonged hospital stay correlated with increased pDDI risk.
Co-morbidities, alcohol use, and advanced age were also significant predictors.
Lexicomp identified more pDDIs than Micromedex, although both databases showed moderate agreement.
Clinical Implications
Healthcare professionals should monitor for potential drug-drug interactions among pulmonary inpatients.
Conclusion
The findings highlight the prevalence of pDDIs among pulmonary inpatients.
Narrative review describes how physiologic stressors accumulate from induction through postintubation care and may contribute to cardiovascular deterioration during airway management.
